Cardiologists, Primary Care Physicians, Hospitalists, Internal Medicine Physicians
Congestive Heart Failure; Heart Failure
| 1. | Describe the epidemiology of heart failure (HF) , including the risk factors and associated clinical consequences. | 2. | Describe the pathophysiology of patients with systolic heart failure. |
| 3. | Implement current optimal medical therapy for the treatment of chronic congestive heart failure | 4. | Discuss the role of vasoactive peptides in the regulation of the cardiovascular system |
| 5. | Assess current data and potential role of new and emerging therapies for the treatment of heart failure with reduced ejection fraction |
| 1. | Describe the epidemiology of heart failure (HF) , including the risk factors and associated clinical consequences. |
| 2. | Describe the pathophysiology of patients with systolic heart failure. |
| 3. | Implement current optimal medical therapy for the treatment of chronic congestive heart failure |
| 4. | Discuss the role of vasoactive peptides in the regulation of the cardiovascular system |
| 5. | Assess current data and potential role of new and emerging therapies for the treatment of heart failure with reduced ejection fraction |
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Javed Butler, MD, MPH, FAHA, FACC | Dr. Butler has been a consult for Amgen, Bayer, Cardiocell, Celladon, Jannsen, Novartis, Relypsa, Stealth, Peptide,Trevena, Z Pharma, and Zensun. He is also on the speakers bureau for Novartis. Additionally, he has recieved research grants from NIH and the European Union. |
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. |